SAN DIEGO, Sept. 13 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that Malvina Laudicina has joined Cadence's management team as Vice President, Regulatory Affairs and Quality Assurance. She will lead the regulatory and quality assurance activities for the Company's two ongoing Phase III clinical development programs.
"Malvina's extensive experience in the area of regulatory filings and clinical development requirements is a great asset to Cadence and will play a vital role in helping us achieve our clinical development and regulatory objectives for our two Phase III product candidates, intravenous acetaminophen for the treatment of acute pain and fever and Omigard(TM) for the prevention of catheter related infections," stated Jim Breitmeyer, M.D., Executive Vice President, Development and Chief Medical Officer of Cadence.
Ms. Laudicina joins Cadence from Pfizer where she was most recently
involved in safety and risk management activities at the company's La Jolla
site. Also at Pfizer, as Executive Director and Regulatory Site Head, she
had responsibility for four therapeutic areas and led the regulatory team
responsible for the registration of Sutent(R) (sunitinib malate), a drug
approved by the U.S. Food and Drug Administration (FDA) for the treatment
of advanced kidney cancer and gastrointestinal stromal tumors. Prior to
Pfizer, Ms. Laudicina held senior regulatory and clinical research
positions at Prometheus Laboratories, Dura Pharmaceuticals and
Schering-Plough Corporation. She received her B.S. in Che
|SOURCE Cadence Pharmaceuticals, Inc.|
Copyright©2007 PR Newswire.
All rights reserved